NCT05998304View on ClinicalTrials.gov

ADME Study of [14C] Yiqibuvir in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

September 12, 2023

Study Completion Date

September 12, 2023

Conditions
Healthy Male Subjects
Interventions
DRUG

[14C] Yiqibuvir

600 mg suspension containing 100µCi of \[14C\] Yiqibuvir

Trial Locations (1)

Unknown

Shanghai xuhui central hospital, Shanghai

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY